Is there a shortage of Tislelizumab-jsgr?

No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).

Has Tislelizumab-jsgr been recalled?

No recall linked to the products of this medicine appears in the FDA enforcement reports we use.

Who makes Tislelizumab-jsgr?

1 company lists prescription products of Tislelizumab-jsgr in the FDA NDC Directory, including BeOne Medicines USA, Inc..

Tislelizumab-jsgr (Tevimbra): uses, warnings, recalls

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

Is there a shortage of Tislelizumab-jsgr?: No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Tislelizumab-jsgr been recalled?: No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Tislelizumab-jsgr?: 1 company lists prescription products of Tislelizumab-jsgr in the FDA NDC Directory, including BeOne Medicines USA, Inc..

What Tislelizumab-jsgr is used for

We did not find an “Indications and Usage” section in the FDA labels for this medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Forms and how it is given

Dosage forms	Injection, solution, concentrate
Route	Intravenous
Prescription products	2 in the FDA NDC Directory
Brand names	Tevimbra

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

BeOne Medicines USA, Inc.2 products

FDA approval history

BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.

Brand and biologic applications
Application	Sponsor	Approved	Later changes approved
BLA761232 TEVIMBRA	Beigene	March 13, 2024	12, latest August 25, 2026 2026: Efficacy · 2025: Efficacy · 2025: Efficacy

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

FDA labels (SPL)	0
FDA applications	BLA761232
Active ingredients (FDA)	TISLELIZUMAB

Sources

NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers

Tislelizumab-jsgr